Plant-Derived Bioactive Compounds and Their Molecular Mechanisms Targeting Key Cancer Signaling Pathways for Therapeutic Intervention and Translational Oncology Applications

Liam Patrick Wilson [1*], Grace Elizabeth O'Connor [2], Noah Benjamin Thompson [3], Chloe Margaret Collins [4]
[1] PhD, Centre for Pharmaceutical Nanotechnology, Monash University, Melbourne, Australia.
[2] PhD, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
[3] PhD, Drug Delivery and Biomaterials Group, University of Sydney, Sydney, Australia.
[4] PhD, Precision Oncology Laboratory, University of Melbourne, Melbourne, Australia.

* Corresponding Author: **Liam Patrick Wilson**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 01
January – February 2024
Received: 11-12-2023
Accepted: 12-01-2024
Published: 14-02-2024
Page No: 237-251

Abstract
Cancer remains a leading cause of mortality worldwide, with dysregulated signaling pathways contributing significantly to tumor initiation, progression, metastasis, and therapeutic resistance. Aberrant activation of critical molecular cascades including the phosphoinositide 3-kinase/protein kinase B pathway, mitogen-activated protein kinase pathway, Wnt/β-catenin pathway, and nuclear factor-kappa B pathway drives oncogenic transformation and sustains malignant phenotypes across diverse cancer types. Plant-derived bioactive compounds have emerged as promising therapeutic agents capable of modulating these pathways through multifaceted molecular mechanisms. This review comprehensively examines the anticancer potential of major phytochemicals including curcumin, resveratrol, epigallocatechin gallate, quercetin, genistein, and other polyphenolic compounds, exploring their capacity to induce apoptosis, promote cell cycle arrest, inhibit angiogenesis, and suppress metastatic potential. We critically analyze preclinical evidence from *in vitro* and *in vivo* models demonstrating the efficacy of these compounds in targeting specific molecular nodes within dysregulated signaling networks. Furthermore, we evaluate clinical studies and translational insights that highlight both the therapeutic promise and challenges associated with plant-derived anticancer agents. The synergistic potential of combinatorial strategies integrating phytochemicals with conventional chemotherapy, radiotherapy, and targeted therapies is discussed in the context of enhanced efficacy and reduced toxicity. Finally, we address pharmacokinetic limitations, bioavailability concerns, regulatory considerations, and future directions toward the development of precision oncology approaches utilizing plant-derived compounds as standardized, evidence-based therapeutic interventions in translational medicine.

DOI:

Keywords: Plant-derived compounds, Cancer signaling pathways, Phytochemicals, Molecular targets, Preclinical studies, Clinical evidence, Precision oncology, Translational therapeutics

Introduction

Cancer represents a heterogeneous group of diseases characterized by uncontrolled cellular proliferation, evasion of apoptosis, sustained angiogenesis, tissue invasion, and metastatic dissemination [1]. Despite significant advances in cancer therapeutics, including the development of targeted therapies and immunotherapeutic approaches, the global burden of cancer continues to escalate, with an estimated 19.3 million new cases and nearly 10 million cancer-related deaths reported annually [2]. The complexity of cancer biology, coupled with the development of therapeutic resistance and significant treatment-related toxicities,

necessitates the exploration of novel therapeutic strategies that can effectively target malignant cells while minimizing adverse effects on normal tissues [3].

The dysregulation of intracellular signaling pathways constitutes a fundamental hallmark of cancer, providing selective advantages that enable tumor cells to proliferate autonomously, resist cell death signals, and adapt to hostile microenvironmental conditions [4]. These aberrant signaling cascades not only drive oncogenic transformation but also facilitate tumor progression, metastatic spread, and resistance to conventional therapeutic modalities [5]. Among the most frequently dysregulated pathways in human malignancies are the phosphoinositide 3-kinase/protein kinase B pathway, the mitogen-activated protein kinase pathway, the Wnt/β-catenin pathway, and the nuclear factor-kappa B pathway, each playing pivotal roles in regulating cellular survival, proliferation, differentiation, and inflammatory responses [6].

For millennia, medicinal plants have served as invaluable sources of therapeutic agents for the treatment of various human ailments, including cancer [7]. Ethnopharmacological knowledge accumulated across diverse cultures has guided the identification of numerous plant species with anticancer properties, many of which have subsequently undergone rigorous scientific investigation [8]. Plant-derived bioactive compounds, collectively termed phytochemicals, encompass a structurally diverse array of secondary metabolites including polyphenols, alkaloids, terpenoids, flavonoids, and organosulfur compounds [9]. These natural products have demonstrated remarkable capacity to modulate multiple molecular targets simultaneously, a property that distinguishes them from conventional single-target synthetic drugs and may contribute to their therapeutic efficacy against complex diseases such as cancer [10].

The renewed interest in plant-derived anticancer agents reflects both the limitations of current therapeutic approaches and the recognition that nature provides a vast chemical diversity that has been evolutionarily optimized for biological activity [11]. Approximately 60 percent of currently approved anticancer drugs are either natural products or derivatives thereof, underscoring the historical and ongoing importance of natural sources in oncology drug discovery [12]. However, the transition from traditional use and preliminary laboratory observations to evidence-based clinical application requires comprehensive understanding of the molecular mechanisms through which phytochemicals exert their anticancer effects, rigorous evaluation of their efficacy and safety in preclinical and clinical settings, and optimization of pharmaceutical formulations to overcome inherent limitations such as poor bioavailability and rapid metabolism [13].

This comprehensive review aims to critically examine the anticancer potential of major plant-derived bioactive compounds through the lens of their molecular interactions with key cancer signaling pathways. We focus specifically on compounds that have demonstrated capacity to modulate the phosphoinositide 3-kinase/protein kinase B, mitogen-activated protein kinase, Wnt/β-catenin, and nuclear factor-kappa B pathways, given the central roles these cascades play in cancer biology and their status as validated therapeutic targets [14]. By integrating evidence from molecular studies, preclinical models, and clinical investigations, we seek to provide a holistic perspective on the translational potential of plant-derived compounds in modern oncology, addressing both their promise as therapeutic agents and the challenges that must be overcome to realize their clinical utility.

Overview of Cancer Signaling Pathways and Dysregulation

The malignant transformation of normal cells into cancer involves the accumulation of genetic and epigenetic alterations that disrupt the finely tuned regulatory networks governing cellular homeostasis [15]. Central to this process is the dysregulation of signal transduction pathways that normally coordinate cellular responses to extracellular stimuli, including growth factors, cytokines, and stress signals [16]. In cancer, these pathways become aberrantly activated or inactivated through various mechanisms including activating mutations in oncogenes, inactivating mutations in tumor suppressor genes, chromosomal rearrangements, gene amplification, and epigenetic modifications [17]. The resultant signaling imbalances confer upon cancer cells the ability to proliferate independently of external growth signals, resist apoptotic stimuli, sustain angiogenesis, and acquire invasive and metastatic capabilities [18].

The phosphoinositide 3-kinase/protein kinase B pathway represents one of the most frequently dysregulated signaling cascades in human cancer, with alterations detected in up to 70 percent of malignancies across diverse tissue types [19]. This pathway is initiated by the activation of receptor tyrosine kinases or G protein-coupled receptors, leading to the recruitment and activation of phosphoinositide 3-kinase enzymes that phosphorylate phosphatidylinositol 4,5-bisphosphate to generate phosphatidylinositol 3,4,5-trisphosphate [20]. This lipid second messenger serves as a docking site for pleckstrin homology domain-containing proteins including protein kinase B and phosphoinositide-dependent kinase 1, resulting in the phosphorylation and activation of protein kinase B [21]. Once activated, protein kinase B phosphorylates numerous downstream substrates that regulate critical cellular processes including glucose metabolism, protein synthesis, cell survival, and cell cycle progression [22]. The pathway is negatively regulated by the phosphatase and tensin homolog tumor suppressor, which dephosphorylates phosphatidylinositol 3,4,5-trisphosphate, thereby antagonizing phosphoinositide 3-kinase signaling [23]. Loss of phosphatase and tensin homolog function through mutation, deletion, or epigenetic silencing occurs in a substantial proportion of human cancers, resulting in constitutive activation of protein kinase B and downstream effectors [24].

The mitogen-activated protein kinase pathways constitute a family of evolutionarily conserved signaling modules that transduce extracellular signals to the nucleus, regulating gene expression programs that control cell proliferation, differentiation, survival, and stress responses [25]. The classical mitogen-activated protein kinase cascade consists of three sequentially activated kinases: a mitogen-activated protein kinase kinase kinase, a mitogen-activated protein kinase kinase, and a mitogen-activated protein kinase [26]. In mammals, four major mitogen-activated protein kinase subfamilies have been identified: extracellular signal-regulated kinase 1/2, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase, and extracellular signal-regulated kinase 5 [27]. The extracellular signal-regulated kinase 1/2 pathway is particularly important in cancer biology, as it promotes cell proliferation, survival, and motility in response to growth factor stimulation [28]. Aberrant activation of this pathway occurs frequently in cancer through mutations in upstream regulators such as rat sarcoma viral oncogene

homolog and rapidly accelerated fibrosarcoma kinases, with rat sarcoma mutations present in approximately 30 percent of all human cancers [29].

The Wnt/β-catenin pathway plays essential roles in embryonic development, tissue homeostasis, and stem cell maintenance, while its dysregulation contributes to tumorigenesis in multiple cancer types, most notably colorectal cancer [30]. In the absence of Wnt ligands, cytoplasmic β-catenin is sequestered by a destruction complex comprising adenomatous polyposis coli, axis inhibition protein, glycogen synthase kinase 3 beta, and casein kinase 1 alpha, which phosphorylates β-catenin and targets it for ubiquitin-mediated proteasomal degradation [31]. Binding of Wnt ligands to Frizzled receptors and low-density lipoprotein receptor-related protein 5/6 co-receptors leads to recruitment of Dishevelled proteins and subsequent disruption of the destruction complex, allowing β-catenin to accumulate in the cytoplasm and translocate to the nucleus [32]. Nuclear β-catenin interacts with T-cell factor/lymphoid enhancer-binding factor transcription factors to activate expression of target genes involved in cell proliferation, survival, and stemness [33]. Mutations in adenomatous polyposis coli or β-catenin genes that stabilize β-catenin protein are common in colorectal cancer and several other malignancies, resulting in constitutive pathway activation [34].

The nuclear factor-kappa B signaling pathway serves as a master regulator of inflammatory and immune responses while also playing crucial roles in cell survival, proliferation, and transformation [35]. The nuclear factor-kappa B family comprises five transcription factor subunits that form homo- and heterodimeric complexes, with the p65/p50 heterodimer representing the most abundant form in most cell types [36]. In unstimulated cells, nuclear factor-kappa B dimers are retained in the cytoplasm through interaction with inhibitor of kappa B proteins [37]. Various stimuli including pro-inflammatory cytokines, pathogen-associated molecular patterns, and genotoxic stress activate the inhibitor of kappa B kinase complex, which phosphorylates inhibitor of kappa B proteins, marking them for ubiquitination and proteasomal degradation [38]. Liberation of nuclear factor-kappa B allows its nuclear translocation and binding to kappa B DNA elements in target gene promoters, inducing expression of genes involved in inflammation, immunity, cell survival, and proliferation [39]. Constitutive nuclear factor-kappa B activation has been documented in numerous hematological and solid malignancies, contributing to oncogenesis through promotion of cell survival, inhibition of apoptosis, enhancement of angiogenesis, and facilitation of metastasis [40].

Cross-talk between these major signaling pathways adds an additional layer of complexity to cancer biology, as activation or inhibition of one pathway can influence the activity of others through shared regulatory nodes and feedback mechanisms [41]. For example, protein kinase B can activate nuclear factor-kappa B signaling through phosphorylation of inhibitor of kappa B kinase, while nuclear factor-kappa B can transcriptionally upregulate protein kinase B expression, creating a positive feedback loop that sustains both pathways [42]. Similarly, the mitogen-activated protein kinase and phosphoinositide 3-kinase pathways can be co-activated downstream of receptor tyrosine kinases, and inhibition of one pathway may lead to compensatory upregulation of the other [43]. Understanding these intricate signaling networks and their dysregulation in cancer is essential for identifying effective therapeutic strategies and for appreciating the potential advantages of multi-targeted approaches such as those offered by plant-derived bioactive compounds [44].

Plant-Derived Bioactive Compounds with Anticancer Properties

Plants synthesize an extraordinary diversity of secondary metabolites that serve various ecological functions including defense against pathogens and herbivores, attraction of pollinators, and adaptation to environmental stresses [45]. These phytochemicals, numbering in the hundreds of thousands of distinct structures, represent a vast reservoir of biologically active compounds with potential therapeutic applications in human disease [46]. The systematic investigation of plant-derived compounds for anticancer activity has yielded numerous promising candidates, several of which have advanced to clinical development or have been incorporated into standard oncological practice [47]. The major classes of phytochemicals with demonstrated anticancer properties include polyphenols, flavonoids, alkaloids, terpenoids, and organosulfur compounds, each exhibiting distinct structural characteristics and molecular mechanisms of action [48].

Curcumin, a diferuloylmethane compound derived from the rhizome of Curcuma longa, represents one of the most extensively studied plant-derived anticancer agents [49]. This polyphenolic compound has demonstrated pleiotropic biological activities including anti-inflammatory, antioxidant, and anticancer properties across diverse experimental systems [50]. Curcumin has been shown to modulate multiple signaling pathways implicated in cancer, including the phosphoinositide 3-kinase/protein kinase B, mitogen-activated protein kinase, nuclear factor-kappa B, and Wnt/β-catenin pathways, through mechanisms involving direct interaction with signaling proteins, modulation of gene expression, and regulation of microRNA expression [51]. The compound induces apoptosis in cancer cells through both intrinsic and extrinsic pathways, promotes cell cycle arrest at multiple checkpoints, inhibits angiogenesis by downregulating vascular endothelial growth factor expression, and suppresses metastasis by interfering with epithelial-mesenchymal transition [52]. Despite its promising preclinical profile, curcumin faces significant challenges related to poor aqueous solubility, low bioavailability, and rapid metabolism, necessitating the development of improved formulations to enhance its therapeutic potential.

Resveratrol, a stilbenoid polyphenol found in grapes, berries, and peanuts, has garnered considerable attention for its purported health-promoting properties, including cardioprotection and cancer prevention. This compound exists in cis and trans isomeric forms, with trans-resveratrol exhibiting greater biological activity. Resveratrol exerts anticancer effects through multiple mechanisms including activation of sirtuin 1, a nicotinamide adenine dinucleotide-dependent deacetylase that regulates cellular metabolism and stress responses, modulation of the phosphoinositide 3-kinase/protein kinase B and mitogen-activated protein kinase pathways, and inhibition of cyclooxygenase enzymes involved in inflammatory responses. The compound has demonstrated capacity to induce apoptosis and cell cycle arrest in various cancer cell lines, suppress tumor growth in animal models, and enhance the efficacy of conventional chemotherapeutic agents. However, similar to curcumin, resveratrol suffers from limited bioavailability due to

extensive first-pass metabolism, rapid glucuronidation, and sulfation, which may limit its clinical utility.

Epigallocatechin gallate, the most abundant and biologically active catechin in green tea, has been extensively investigated for its cancer preventive and therapeutic properties. This polyphenolic compound exhibits potent antioxidant activity while paradoxically generating reactive oxygen species under certain conditions, contributing to its complex biological effects. Epigallocatechin gallate modulates numerous signaling pathways relevant to cancer including the epidermal growth factor receptor, mitogen-activated protein kinase, phosphoinositide 3-kinase/protein kinase B, nuclear factor-kappa B, and Wnt/β-catenin pathways. The compound has been shown to induce apoptosis, inhibit cell proliferation, suppress angiogenesis, and prevent metastasis in preclinical cancer models. Additionally, epigallocatechin gallate can modulate epigenetic mechanisms through inhibition of DNA methyltransferases and histone deacetylases, potentially reversing aberrant epigenetic silencing of tumor suppressor genes. Epidemiological studies have suggested an inverse association between green tea consumption and cancer risk in certain populations, although clinical trials evaluating epigallocatechin gallate supplementation have yielded mixed results.

Quercetin, a flavonoid widely distributed in fruits, vegetables, and medicinal plants, possesses diverse biological activities including antioxidant, anti-inflammatory, and anticancer properties. This compound modulates multiple cellular signaling pathways, including inhibition of phosphoinositide 3-kinase/protein kinase B signaling, suppression of mitogen-activated protein kinase activation, and downregulation of nuclear factor-kappa B activity. Quercetin induces apoptosis in cancer cells through activation of caspase cascades, promotes cell cycle arrest primarily at the G1 phase through modulation of cyclin-dependent kinases and their inhibitors, and inhibits angiogenesis by downregulating hypoxia-inducible factor 1-alpha and vascular endothelial growth factor expression. The compound has also demonstrated capacity to overcome multidrug resistance in cancer cells by inhibiting ATP-binding cassette transporters, suggesting potential utility in combination with conventional chemotherapeutic agents. As with many other flavonoids, quercetin exhibits limited oral bioavailability due to extensive intestinal and hepatic metabolism, although various formulation strategies have been explored to address this limitation.

Genistein, an isoflavone predominantly found in soybeans and soy products, has been extensively studied for its potential role in cancer prevention and treatment, particularly in hormone-dependent malignancies. This compound can bind to estrogen receptors and exert both estrogenic and anti-estrogenic effects depending on the tissue context and hormonal milieu, a property that has stimulated interest in its potential for breast and prostate cancer prevention. Beyond its hormonal effects, genistein modulates multiple signaling pathways implicated in cancer including inhibition of tyrosine kinases, suppression of nuclear factor-kappa B activation, downregulation of the phosphoinositide 3-kinase/protein kinase B pathway, and inhibition of topoisomerase II. The compound induces apoptosis, promotes cell cycle arrest, inhibits angiogenesis, and suppresses metastasis in various experimental cancer models. Epidemiological observations suggesting lower cancer incidence in populations with high soy consumption have motivated clinical investigations of genistein supplementation, although results have been variable and the optimal dose and target population remain subjects of ongoing research.

Additional plant-derived compounds with significant anticancer potential include the alkaloids vincristine and vinblastine from Catharanthus roseus, which have been successfully developed into clinically approved chemotherapeutic agents that disrupt microtubule dynamics. Paclitaxel, a diterpene alkaloid originally isolated from the bark of Taxus brevifolia, represents another major success story in natural product-based cancer therapy, functioning as a microtubule-stabilizing agent widely used in the treatment of ovarian, breast, and lung cancers. Camptothecin and its derivatives irinotecan and topotecan, derived from Camptotheca acuminata, act as topoisomerase I inhibitors and have found clinical application in colorectal and ovarian cancers. These examples demonstrate that plant-derived compounds can indeed be developed into effective anticancer therapeutics when their mechanisms of action are clearly elucidated, their pharmaceutical properties are optimized, and rigorous clinical evaluation is conducted.

Molecular Mechanisms of Action on Key Signaling Pathways

The anticancer efficacy of plant-derived bioactive compounds is mediated through their capacity to modulate multiple molecular targets within dysregulated signaling pathways, distinguishing them from conventional single-target synthetic drugs. This multi-targeting property may contribute to enhanced therapeutic efficacy and reduced likelihood of resistance development, as cancer cells would need to simultaneously develop compensatory mechanisms across multiple pathways to evade the effects of these compounds. Understanding the precise molecular mechanisms through which phytochemicals interact with cancer signaling pathways is essential for rational therapeutic development and for identifying biomarkers that may predict response to these agents.

Curcumin exerts its anticancer effects through modulation of the phosphoinositide 3-kinase/protein kinase B pathway at multiple levels. The compound has been shown to inhibit receptor tyrosine kinase activation, thereby preventing the upstream initiation of the pathway. Additionally, curcumin can directly suppress phosphoinositide 3-kinase activity and decrease phosphorylation of protein kinase B at both threonine 308 and serine 473 residues, which are essential for its full activation. Downstream of protein kinase B, curcumin modulates the activity of mammalian target of rapamycin complex 1, a key regulator of protein synthesis and cell growth, through mechanisms involving activation of tuberous sclerosis complex 2 and AMP-activated protein kinase. The compound also upregulates expression of phosphatase and tensin homolog, the principal negative regulator of the phosphoinositide 3-kinase/protein kinase B pathway, through transcriptional mechanisms and protection from degradation. These multi-level effects result in comprehensive suppression of pathway activity and downstream biological consequences including reduced cell proliferation, decreased protein synthesis, and enhanced apoptotic susceptibility.

The interaction of curcumin with the nuclear factor-kappa B pathway involves inhibition of inhibitor of kappa B kinase activity, prevention of inhibitor of kappa B alpha

phosphorylation and degradation, and subsequent retention of nuclear factor-kappa B in the cytoplasm. Additionally, curcumin can directly interact with the p65 subunit of nuclear factor-kappa B, preventing its binding to DNA and inhibiting transcription of pro-survival and pro-inflammatory target genes. This suppression of nuclear factor-kappa B activity contributes to the anti-inflammatory and pro-apoptotic effects of curcumin and may also sensitize cancer cells to conventional therapeutic modalities that rely on induction of DNA damage or oxidative stress. The compound further modulates mitogen-activated protein kinase signaling through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and activation of stress-responsive c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways, contributing to induction of apoptosis and cell cycle arrest.

Resveratrol interacts with multiple nodes within cancer signaling networks through both receptor-mediated and receptor-independent mechanisms. The compound can bind to and activate estrogen receptors, particularly estrogen receptor beta, potentially contributing to its effects in hormone-responsive cancers. More broadly relevant to cancer biology is resveratrol's capacity to activate sirtuin 1, which deacetylates numerous protein substrates including p53, forkhead box O transcription factors, and nuclear factor-kappa B, thereby modulating cellular stress responses, metabolism, and inflammation. Resveratrol inhibits phosphoinositide 3-kinase/protein kinase B signaling through mechanisms involving upregulation of phosphatase and tensin homolog expression and direct suppression of protein kinase B phosphorylation. The compound also modulates mitogen-activated protein kinase pathways, generally inhibiting proliferative extracellular signal-regulated kinase signaling while activating stress-responsive c-Jun N-terminal kinase and p38 pathways. Additionally, resveratrol suppresses nuclear factor-kappa B activation through inhibition of inhibitor of kappa B kinase and prevention of nuclear translocation of the p65 subunit.

Epigallocatechin gallate exerts its anticancer effects through remarkably diverse molecular mechanisms reflecting its capacity to interact with numerous cellular targets. The compound directly binds to and inhibits receptor tyrosine kinases including epidermal growth factor receptor, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor, thereby blocking the upstream activation of multiple downstream signaling cascades. Epigallocatechin gallate inhibits phosphoinositide 3-kinase activity and protein kinase B phosphorylation, leading to decreased mammalian target of rapamycin signaling and reduced cell proliferation and survival. The compound modulates mitogen-activated protein kinase pathways, typically inhibiting extracellular signal-regulated kinase 1/2 activation while promoting activation of c-Jun N-terminal kinase, contributing to induction of apoptosis. Nuclear factor-kappa B signaling is suppressed by epigallocatechin gallate through inhibition of inhibitor of kappa B kinase activity and prevention of inhibitor of kappa B alpha degradation. Notably, epigallocatechin gallate also modulates epigenetic regulatory mechanisms through inhibition of DNA methyltransferases and histone deacetylases, potentially reversing aberrant epigenetic silencing of tumor suppressor genes.

Quercetin modulates cancer signaling pathways through mechanisms involving both direct protein interactions and transcriptional regulation. The compound inhibits phosphoinositide 3-kinase activity through direct binding to the enzyme's ATP-binding site, resulting in decreased protein kinase B phosphorylation and reduced downstream signaling. Quercetin suppresses extracellular signal-regulated kinase 1/2 activation while promoting activation of stress-responsive mitogen-activated protein kinases, contributing to its pro-apoptotic effects. The compound inhibits nuclear factor-kappa B signaling through multiple mechanisms including suppression of inhibitor of kappa B kinase activity, prevention of inhibitor of kappa B alpha phosphorylation, and direct inhibition of nuclear factor-kappa B DNA-binding activity. Additionally, quercetin can modulate expression of genes encoding signaling pathway components through effects on transcription factors and epigenetic regulators. The compound has also been shown to inhibit heat shock protein 90, a molecular chaperone essential for stability and function of numerous signaling proteins including protein kinase B and receptor tyrosine kinases, providing an additional mechanism through which it can disrupt cancer signaling networks.

Genistein exerts its anticancer effects through inhibition of tyrosine kinases, a property that underlies many of its effects on signaling pathways. The compound competitively inhibits the ATP-binding sites of various tyrosine kinases including epidermal growth factor receptor, human epidermal growth factor receptor 2, and members of the Src family, thereby preventing receptor autophosphorylation and downstream signal propagation. This broad tyrosine kinase inhibitory activity results in suppression of both the phosphoinositide 3-kinase/protein kinase B and mitogen-activated protein kinase pathways. Genistein also inhibits nuclear factor-kappa B activation through mechanisms involving suppression of inhibitor of kappa B kinase activity and prevention of p65 nuclear translocation. In the context of Wnt/β-catenin signaling, genistein has been shown to promote β-catenin degradation and inhibit its transcriptional activity, potentially through modulation of the destruction complex. The compound additionally modulates expression of genes involved in cell cycle regulation, apoptosis, and metastasis through effects on transcription factors including activator protein-1 and specificity protein 1.

The capacity of plant-derived compounds to simultaneously modulate multiple signaling pathways represents a potential therapeutic advantage, particularly in the context of cancer cells that have acquired resistance to single-target therapies through compensatory pathway activation. However, this pleiotropy also complicates the identification of the most critical molecular targets responsible for therapeutic effects and may contribute to variability in responses across different cancer types and genetic contexts. Comprehensive systems biology approaches integrating genomic, transcriptomic, proteomic, and metabolomic analyses are increasingly being applied to elucidate the full spectrum of molecular changes induced by phytochemicals and to identify predictive biomarkers that may guide patient selection in clinical applications.

Preclinical Evidence: *In vitro* and *In vivo* Studies

The anticancer potential of plant-derived bioactive compounds has been extensively evaluated in preclinical models ranging from cancer cell lines cultured *in vitro* to sophisticated animal models that recapitulate key aspects of human cancer biology. These studies have provided valuable mechanistic insights into the molecular effects of

phytochemicals and have generated preliminary evidence of efficacy that serves as the foundation for clinical translation. However, careful interpretation of preclinical data is essential, as findings from reductionist *in vitro* systems and rodent models may not fully predict clinical outcomes in human patients.

In vitro studies utilizing cancer cell lines have demonstrated that curcumin exhibits dose-dependent antiproliferative and pro-apoptotic effects across diverse cancer types including breast, prostate, colon, lung, and pancreatic cancers. Treatment with curcumin at concentrations ranging from 10 to 50 micromolar typically induces cell cycle arrest, predominantly at the G1/S or G2/M transitions, associated with modulation of cyclin-dependent kinases, cyclins, and cyclin-dependent kinase inhibitors. Apoptosis induction occurs through both the intrinsic mitochondrial pathway, characterized by cytochrome c release and caspase-9 activation, and the extrinsic death receptor pathway involving caspase-8 activation. Curcumin has been shown to downregulate expression of anti-apoptotic proteins including B-cell lymphoma 2 and B-cell lymphoma-extra large while upregulating pro-apoptotic proteins such as Bcl-2-associated X protein and Bcl-2 homologous antagonist/killer. *In vivo* studies utilizing xenograft and syngeneic tumor models have demonstrated that oral or intraperitoneal administration of curcumin can suppress tumor growth, reduce tumor volume, and prolong survival in tumor-bearing animals. For example, curcumin administration at doses of 100 to 500 milligrams per kilogram body weight has been shown to inhibit growth of human breast cancer xenografts in nude mice by up to 60 percent compared to vehicle-treated controls.

Resveratrol has demonstrated antiproliferative effects against multiple cancer cell lines *in vitro*, with concentrations of 10 to 100 micromolar typically required to achieve significant growth inhibition. The compound induces cell cycle arrest primarily at the S phase through mechanisms involving upregulation of p21 and p53, while also promoting apoptosis through activation of caspase cascades. Resveratrol has been shown to inhibit cancer cell migration and invasion *in vitro*, effects attributed to downregulation of matrix metalloproteinases and suppression of epithelial-mesenchymal transition. *In vivo* studies have yielded somewhat variable results, with some experiments demonstrating significant tumor growth inhibition while others have shown more modest effects. The discrepancy between *in vitro* and *in vivo* efficacy may reflect the poor bioavailability and rapid metabolism of resveratrol following oral administration. Nevertheless, studies utilizing tumor xenograft models have shown that resveratrol administration can reduce tumor incidence, delay tumor onset, and decrease tumor multiplicity in chemically induced carcinogenesis models.

Epigallocatechin gallate exhibits potent antiproliferative effects against cancer cell lines *in vitro*, typically at concentrations of 20 to 100 micromolar. The compound induces apoptosis through multiple mechanisms including generation of reactive oxygen species, mitochondrial membrane depolarization, and activation of caspase cascades. Epigallocatechin gallate has been shown to inhibit telomerase activity in cancer cells, potentially limiting their replicative potential. Studies of cancer cell invasion and metastasis *in vitro* have demonstrated that epigallocatechin gallate can suppress cell migration, inhibit matrix metalloproteinase activity, and prevent adhesion to extracellular matrix components. *In vivo* studies have provided evidence that epigallocatechin gallate administration can reduce tumor growth in xenograft models and decrease tumor incidence in transgenic cancer models. For instance, oral administration of epigallocatechin gallate at doses of 100 to 500 milligrams per kilogram body weight has been shown to inhibit human prostate cancer xenograft growth in nude mice by approximately 50 percent. Studies in chemically induced carcinogenesis models have demonstrated that epigallocatechin gallate can reduce tumor multiplicity and delay tumor onset when administered during the initiation, promotion, or progression phases of carcinogenesis.

Quercetin demonstrates dose-dependent antiproliferative effects against various cancer cell lines, with effective concentrations typically ranging from 20 to 100 micromolar. The compound induces cell cycle arrest at multiple phases depending on the cellular context and dose employed, with G1 and G2/M arrests most commonly reported. Quercetin induces apoptosis through both mitochondrial and death receptor pathways, associated with increased expression of pro-apoptotic proteins and decreased expression of anti-apoptotic proteins. *In vitro* studies have shown that quercetin can inhibit angiogenesis by suppressing endothelial cell proliferation, migration, and tube formation, effects mediated through downregulation of vascular endothelial growth factor and hypoxia-inducible factor 1-alpha. *In vivo* studies utilizing tumor xenograft models have demonstrated that quercetin administration can significantly reduce tumor growth, with some studies reporting tumor volume reductions of 40 to 60 percent compared to vehicle-treated controls. However, the poor bioavailability of quercetin following oral administration has limited its efficacy in some animal studies, highlighting the need for improved formulation strategies.

Genistein exhibits antiproliferative effects against cancer cells *in vitro* at concentrations ranging from 10 to 50 micromolar, with particular efficacy observed in hormone-responsive cancers. The compound induces G2/M cell cycle arrest through mechanisms involving increased expression of p21 and decreased expression of cyclin B1 and cell division cycle 2. Genistein promotes apoptosis through activation of caspases and modulation of Bcl-2 family proteins. Studies in breast and prostate cancer models have shown that genistein can inhibit cancer cell invasion and metastasis through suppression of matrix metalloproteinases and inhibition of epithelial-mesenchymal transition. *In vivo* studies have demonstrated that dietary supplementation with genistein can reduce tumor incidence and multiplicity in chemically induced carcinogenesis models and inhibit growth of human cancer xenografts. For example, genistein administration at dietary concentrations of 250 to 1000 parts per million has been shown to reduce mammary tumor incidence by up to 50 percent in carcinogen-treated rats.

Three-dimensional cell culture systems and organoid models have provided more physiologically relevant platforms for evaluating the effects of phytochemicals, as these models better recapitulate the tumor microenvironment, cell-cell interactions, and drug penetration barriers present in solid tumors. Studies utilizing these advanced *in vitro* models have generally confirmed the anticancer effects observed in conventional two-dimensional cell culture while revealing that higher concentrations or longer treatment durations may be required to achieve comparable effects. Patient-derived xenograft models, which involve transplantation of human

tumor tissue directly into immunocompromised mice, provide even more clinically relevant preclinical platforms and have been increasingly utilized to evaluate the efficacy of plant-derived compounds. These models preserve the heterogeneity and microenvironmental characteristics of the original human tumors and may better predict clinical responses than conventional cell line-derived xenografts.

Despite the substantial body of preclinical evidence supporting the anticancer potential of plant-derived compounds, several important limitations must be acknowledged. Many *in vitro* studies employ phytochemical concentrations that far exceed those achievable *in vivo* following oral administration, raising questions about the physiological relevance of observed effects. The poor bioavailability, rapid metabolism, and tissue distribution characteristics of many phytochemicals mean that the concentrations reached in tumor tissues *in vivo* may be insufficient to elicit the molecular effects observed in cell culture. Additionally, the immortalized cancer cell lines commonly used in preclinical studies may not fully represent the genetic and phenotypic heterogeneity of human cancers, potentially leading to overestimation of therapeutic efficacy. These considerations underscore the importance of conducting rigorous pharmacokinetic and pharmacodynamic studies alongside efficacy evaluations and of ultimately validating preclinical findings through carefully designed clinical trials.

Clinical Evaluation and Translational Insights

The translation of promising preclinical findings into clinical applications represents a critical juncture in the development of plant-derived anticancer agents, requiring rigorous evaluation of safety, pharmacokinetics, and efficacy in human subjects. Clinical investigations of phytochemicals have encompassed phase I dose-escalation studies to establish safety profiles and maximum tolerated doses, phase II studies to assess preliminary efficacy in specific cancer types, and a limited number of phase III randomized controlled trials comparing phytochemicals to standard therapies or placebo. While these studies have provided valuable insights into the clinical potential of plant-derived compounds, they have also highlighted significant challenges that must be overcome to realize their therapeutic promise.

Clinical trials evaluating curcumin have been conducted in diverse cancer types including colorectal, pancreatic, breast, and prostate cancers. Phase I studies have established that oral curcumin can be safely administered at doses up to 8 to 12 grams daily, with minimal toxicity reported even at these high doses. However, these studies have consistently documented extremely poor bioavailability, with curcumin and its metabolites detected in plasma at nanomolar concentrations despite gram-level oral dosing. Importantly, curcumin has been detected in colorectal tissue following oral administration, suggesting that direct exposure of gastrointestinal tumors to adequate concentrations may be achievable. A randomized phase II trial in patients with advanced pancreatic cancer evaluated the combination of curcumin with gemcitabine chemotherapy, demonstrating that curcumin administration was safe and well-tolerated but did not significantly improve overall survival or progression-free survival compared to gemcitabine alone. A phase II study in patients with familial adenomatous polyposis demonstrated that combined curcumin and quercetin supplementation resulted in significant reductions in polyp number and size, suggesting potential for chemoprevention in high-risk populations. These mixed results highlight the challenges of achieving therapeutic tissue concentrations and underscore the need for improved formulations with enhanced bioavailability.

Resveratrol has been evaluated in clinical trials primarily in the context of cancer prevention and as an adjunct to conventional therapies. Phase I studies have established that resveratrol can be safely administered orally at doses up to 5 grams daily, although gastrointestinal adverse effects become more common at higher doses. Pharmacokinetic studies have confirmed that resveratrol undergoes extensive first-pass metabolism, with parent compound detected in plasma at low nanomolar to low micromolar concentrations and metabolites including resveratrol glucuronides and sulfates predominating. A pilot study in patients with colorectal cancer and hepatic metastases evaluated high-dose resveratrol administration prior to hepatic surgery, demonstrating that resveratrol and its metabolites could be detected in hepatic tissue and that markers of cell proliferation were reduced in resveratrol-treated patients. A phase II trial evaluated resveratrol in combination with standard chemotherapy in patients with colorectal cancer, finding that the combination was well-tolerated but did not improve response rates or survival compared to historical controls. Ongoing trials are evaluating novel resveratrol formulations designed to enhance bioavailability and increase tissue concentrations.

Green tea catechins, particularly epigallocatechin gallate, have been extensively studied in clinical cancer prevention and treatment trials. Multiple trials have evaluated green tea extract supplementation in patients with premalignant conditions or early-stage cancers. A landmark study in men with high-grade prostatic intraepithelial neoplasia demonstrated that green tea catechin supplementation significantly reduced progression to prostate cancer compared to placebo, with only 3 percent of catechin-treated subjects developing cancer compared to 30 percent of placebo-treated subjects during the one-year follow-up period. However, a larger subsequent trial failed to replicate these dramatic effects, highlighting the challenges of translating early promising findings into consistent clinical benefits. Studies in women with early-stage breast cancer have evaluated green tea catechin supplementation as an adjunct to standard therapy, with some trials suggesting improvements in biomarkers of oxidative stress and inflammation, though effects on clinical outcomes remain uncertain. Phase I studies of defined epigallocatechin gallate preparations have established safe dosing regimens, typically in the range of 400 to 800 milligrams two to three times daily, with hepatotoxicity emerging as a dose-limiting toxicity at higher doses.

Clinical evaluation of quercetin has been more limited, partly reflecting challenges related to its poor bioavailability and the lack of standardized pharmaceutical-grade preparations. Phase I studies have demonstrated that quercetin can be safely administered at doses up to 1400 milligrams daily, though gastrointestinal side effects and nephrotoxicity have been reported at higher doses. Pharmacokinetic studies have shown that quercetin undergoes extensive conjugation to form glucuronide and sulfate metabolites, with free quercetin detected in plasma at low micromolar concentrations following oral administration of gram-level doses. Small pilot studies have evaluated quercetin in patients with various

solid tumors, generally as part of combination regimens with other phytochemicals or conventional therapies. These studies have documented acceptable tolerability but have not yet demonstrated clear anticancer efficacy, likely reflecting the modest tissue concentrations achieved and the heterogeneity of patient populations studied.

Genistein has been evaluated in clinical trials primarily in hormone-responsive cancers, particularly prostate cancer. Phase I studies established that pure genistein can be safely administered at doses up to 600 milligrams daily, with higher doses associated with gastrointestinal adverse effects. A randomized phase II trial in men with localized prostate cancer evaluated genistein supplementation prior to prostatectomy, demonstrating reductions in serum prostate-specific antigen levels and favorable changes in biomarkers of cell proliferation and apoptosis in prostate tissue. However, larger trials evaluating genistein supplementation for prevention of prostate cancer in high-risk men have not demonstrated significant reductions in cancer incidence. Studies evaluating soy isoflavone mixtures containing genistein as a major component have yielded similarly mixed results, with some trials suggesting modest benefits in reducing cancer biomarkers while others have found no significant effects.

The successful clinical development of plant-derived compounds that are currently used in standard oncology practice provides important lessons for the translation of newer phytochemical candidates. Paclitaxel, derived from Taxus brevifolia and now produced semi-synthetically, exemplifies how natural products can be developed into highly effective chemotherapeutic agents through systematic medicinal chemistry optimization, pharmaceutical formulation development, and rigorous clinical evaluation. The vinca alkaloids vincristine and vinblastine similarly represent successful translations from traditional plant-based remedies to modern chemotherapy. These examples demonstrate that when plant-derived compounds possess sufficiently potent and specific mechanisms of action, and when pharmaceutical challenges can be adequately addressed, they can indeed become valuable components of the cancer therapeutic armamentarium.

A critical insight emerging from clinical evaluations of phytochemicals is that the concentrations required to elicit molecular effects in preclinical models often cannot be safely achieved in patients following oral administration of conventional formulations. This observation has motivated intensive efforts to develop advanced formulations including nanoparticles, liposomes, phospholipid complexes, and solid dispersions designed to enhance absorption, protect from metabolism, and increase tissue delivery. Clinical trials evaluating these next-generation formulations are beginning to demonstrate improved pharmacokinetic profiles and increased bioavailability, potentially enabling achievement of therapeutically relevant tissue concentrations. Additionally, the recognition that some phytochemicals may be more suitable for regional delivery, such as topical application for skin cancers or intraperitoneal administration for ovarian cancer, has opened new avenues for clinical development.

Combination Strategies with Conventional Therapies

The integration of plant-derived bioactive compounds with conventional cancer therapies represents a promising strategy to enhance therapeutic efficacy, overcome resistance mechanisms, and mitigate treatment-related toxicities. This combinatorial approach is supported by several rationales including the capacity of phytochemicals to sensitize cancer cells to chemotherapy and radiotherapy through modulation of survival signaling pathways, their potential to selectively protect normal tissues from treatment-induced damage, and their ability to target cancer stem cells and dormant tumor cell populations that may be resistant to conventional cytotoxic therapies. Preclinical studies have provided extensive evidence supporting the synergistic or additive effects of combining phytochemicals with standard treatments, while clinical investigations are beginning to evaluate the feasibility and efficacy of these approaches in cancer patients.

Curcumin has been extensively studied in combination with various chemotherapeutic agents across diverse cancer types. Preclinical studies have demonstrated that curcumin can enhance the cytotoxic effects of platinum-based agents including cisplatin and oxaliplatin through mechanisms involving suppression of nuclear factor-kappa B-mediated survival signaling, enhancement of apoptosis induction, and inhibition of DNA repair pathways. Combination of curcumin with 5-fluorouracil in colorectal cancer models has shown synergistic effects attributed to curcumin-mediated downregulation of thymidylate synthase and enhancement of drug-induced apoptosis. Studies combining curcumin with taxanes including paclitaxel and docetaxel have demonstrated enhanced microtubule disruption, increased apoptosis, and improved tumor growth inhibition compared to either agent alone. Importantly, curcumin has been shown to reverse chemotherapy resistance in cancer cells through multiple mechanisms including inhibition of drug efflux pumps, suppression of anti-apoptotic proteins, and modulation of epithelial-mesenchymal transition. Clinical trials evaluating curcumin as an adjunct to chemotherapy have been conducted in several cancer types, with most studies demonstrating acceptable tolerability of the combination but variable effects on efficacy outcomes.

The combination of curcumin with radiotherapy has been investigated based on evidence that curcumin can radiosensitize cancer cells while potentially protecting normal tissues. Preclinical studies have shown that curcumin pretreatment enhances radiation-induced cell death through mechanisms involving increased generation of reactive oxygen species, inhibition of DNA repair, and suppression of radiation-induced activation of survival pathways including nuclear factor-kappa B and protein kinase B. Animal studies have demonstrated that curcumin administration in combination with radiotherapy results in enhanced tumor growth inhibition compared to radiotherapy alone. Clinical trials are evaluating curcumin supplementation during radiotherapy in patients with head and neck cancer, rectal cancer, and other malignancies, with preliminary data suggesting potential benefits in reducing radiation-induced mucositis and dermatitis while possibly enhancing tumor response.

Resveratrol has been investigated in combination with various chemotherapeutic agents with evidence of synergistic interactions. Studies combining resveratrol with doxorubicin have demonstrated enhanced cytotoxicity against cancer cells while protective effects against doxorubicin-induced cardiotoxicity in normal cardiomyocytes. The combination of resveratrol with gemcitabine in pancreatic cancer models has shown enhanced tumor growth inhibition attributed to resveratrol-mediated suppression of gemcitabine-induced

activation of compensatory survival pathways. Resveratrol has been shown to enhance the efficacy of targeted therapies including epidermal growth factor receptor inhibitors and mammalian target of rapamycin inhibitors through complementary inhibition of downstream signaling pathways. Studies combining resveratrol with immunotherapy approaches are emerging, based on evidence that resveratrol can modulate immune cell function and potentially enhance anti-tumor immunity.

Epigallocatechin gallate has been combined with various chemotherapeutic agents in preclinical studies, demonstrating enhanced cytotoxicity and potential for overcoming drug resistance. The combination of epigallocatechin gallate with platinum compounds has shown synergistic effects in ovarian and lung cancer models, with mechanisms involving enhanced DNA damage, increased apoptosis, and inhibition of DNA repair pathways. Studies combining epigallocatechin gallate with doxorubicin have demonstrated increased cancer cell killing while protection of cardiac cells from doxorubicin-induced toxicity. The combination of epigallocatechin gallate with proteasome inhibitors including bortezomib has shown enhanced anti-myeloma activity attributed to cooperative inhibition of proteasome function and induction of endoplasmic reticulum stress. Clinical trials evaluating green tea catechin supplementation during chemotherapy have been conducted primarily in patients with breast cancer and hematological malignancies, with most studies demonstrating acceptable tolerability though effects on treatment efficacy remain incompletely defined.

Quercetin has been investigated in combination with chemotherapeutic agents based on evidence that it can enhance drug sensitivity and overcome resistance mechanisms. Studies have shown that quercetin can inhibit ATP-binding cassette transporters including P-glycoprotein and multidrug resistance-associated proteins, thereby increasing intracellular accumulation of chemotherapeutic drugs and reversing multidrug resistance. The combination of quercetin with doxorubicin has demonstrated synergistic cytotoxicity in drug-resistant cancer cell lines. Quercetin has been shown to enhance the efficacy of tyrosine kinase inhibitors including gefitinib and erlotinib through complementary inhibition of receptor tyrosine kinase signaling and downstream pathways. Studies combining quercetin with histone deacetylase inhibitors have shown enhanced anti-cancer effects attributed to cooperative epigenetic modulation.

Genistein has been evaluated in combination with chemotherapy and hormone therapy, particularly in hormone-responsive cancers. Studies have demonstrated that genistein can enhance the efficacy of anti-estrogen therapies including tamoxifen through complementary mechanisms involving estrogen receptor modulation and inhibition of growth factor receptor signaling. The combination of genistein with docetaxel in prostate cancer models has shown enhanced tumor growth inhibition compared to either agent alone. Genistein has been shown to enhance the efficacy of epidermal growth factor receptor inhibitors through cooperative inhibition of receptor signaling and downstream pathways. Clinical trials are evaluating genistein supplementation in combination with standard therapies in patients with prostate and breast cancers.

The successful implementation of combination strategies requires careful consideration of dosing, scheduling, and potential drug-drug interactions. Pharmacokinetic interactions between phytochemicals and conventional drugs can occur through modulation of drug-metabolizing enzymes and transporters, potentially altering plasma levels and tissue distribution of chemotherapeutic agents. While such interactions could theoretically be exploited to enhance drug bioavailability, they also raise safety concerns regarding potential increases in treatment-related toxicity. Clinical trials evaluating combination regimens must carefully monitor both efficacy and toxicity outcomes and should incorporate pharmacokinetic assessments to characterize potential drug interactions. The development of optimal combination strategies will likely require systematic evaluation of different dose ratios, treatment schedules, and sequences to identify regimens that maximize therapeutic benefit while minimizing adverse effects.

Safety, Toxicity, and Pharmacokinetic Considerations

The clinical translation of plant-derived bioactive compounds requires comprehensive evaluation of their safety profiles, potential toxicities, and pharmacokinetic characteristics. While phytochemicals are often perceived as safe due to their natural origin and long history of dietary consumption, this assumption may not be valid when these compounds are administered at pharmaceutical doses or in concentrated forms. Understanding the absorption, distribution, metabolism, and excretion properties of phytochemicals is essential for predicting their behavior *in vivo*, optimizing dosing regimens, and identifying potential drug-drug interactions.

Curcumin has demonstrated an excellent safety profile in clinical trials, with doses up to 12 grams daily administered orally for extended periods without serious adverse effects. The most commonly reported side effects are mild gastrointestinal symptoms including diarrhea, nausea, and abdominal discomfort. However, the clinical utility of curcumin is severely limited by its extremely poor bioavailability, with oral absorption estimated at less than 1 percent. Following oral administration, curcumin undergoes rapid metabolism in the intestinal mucosa and liver, primarily through reduction and conjugation reactions yielding glucuronide and sulfate metabolites that are rapidly excreted. The short plasma half-life of approximately one to two hours further contributes to low systemic exposure. Numerous formulation strategies have been developed to address these limitations including incorporation into nanoparticles, liposomes, and phospholipid complexes, co-administration with piperine or other metabolism inhibitors, and chemical modification to produce analogs with improved pharmacokinetic properties. Clinical studies evaluating these advanced formulations have demonstrated bioavailability enhancements ranging from 7-fold to over 100-fold compared to conventional curcumin preparations.

Resveratrol also exhibits an excellent safety profile at doses typically employed in clinical studies, though gastrointestinal adverse effects and occasional instances of hepatotoxicity have been reported at very high doses. The compound undergoes extensive first-pass metabolism, with rapid glucuronidation and sulfation occurring in the intestinal epithelium and liver. Pharmacokinetic studies have shown that following oral administration of 500 milligrams to 5 grams of resveratrol, peak plasma concentrations of parent compound reach only 0.5 to 2 micromolar, far below the concentrations typically required for anticancer effects *in*

vitro. The plasma half-life of resveratrol is approximately 1.5 to 3 hours for the parent compound, though metabolites may have longer half-lives. Interestingly, despite low plasma concentrations, resveratrol and its metabolites accumulate in certain tissues including the gastrointestinal tract, liver, and kidneys, suggesting that local tissue concentrations may be more relevant than systemic exposure for some applications. Various approaches to enhance resveratrol bioavailability are under investigation including nanoparticle formulations, micronized preparations, and co-administration with metabolism inhibitors.

Epigallocatechin gallate is generally well-tolerated when consumed as green tea beverage, but concentrated supplements have been associated with hepatotoxicity in some individuals. Case reports of acute liver injury associated with green tea extract supplementation have prompted regulatory warnings in several countries. The mechanisms underlying this idiosyncratic hepatotoxicity remain incompletely understood but may involve formation of reactive quinone metabolites or individual genetic variations in drug-metabolizing enzymes. Pharmacokinetic studies have shown that epigallocatechin gallate is absorbed following oral administration but undergoes extensive metabolism through methylation, glucuronidation, and sulfation. Peak plasma concentrations following oral administration of 400 to 800 milligrams of epigallocatechin gallate typically reach 1 to 3 micromolar, with a plasma half-life of approximately 3 to 4 hours. The compound exhibits poor lipid solubility and limited ability to cross biological membranes, potentially restricting its distribution to certain tissues. Novel formulations including nanoparticles and pro-drugs are being developed to enhance stability, absorption, and tissue delivery.

Quercetin exhibits acceptable tolerability at doses up to 1 gram daily, though higher doses have been associated with gastrointestinal symptoms and occasional reports of nephrotoxicity. The compound undergoes extensive first-pass metabolism, with absorption ranging from 3 to 17 percent depending on the food matrix and formulation. Quercetin is rapidly conjugated to glucuronide, sulfate, and methyl derivatives, with these metabolites representing the major circulating forms. Peak plasma concentrations following oral administration of 500 milligrams to 1 gram typically reach 1 to 5 micromolar total quercetin equivalents including metabolites, with parent quercetin representing only a small fraction. The plasma half-life of quercetin and its metabolites ranges from 11 to 28 hours, suggesting potential for accumulation with repeated dosing. Emerging evidence suggests that some quercetin conjugates may be deconjugated in tissues by beta-glucuronidase enzymes, potentially regenerating active parent compound at target sites.

Genistein demonstrates good tolerability at doses up to 600 milligrams daily, with gastrointestinal side effects representing the most common adverse events. Concerns have been raised regarding potential hormonal effects of genistein due to its estrogenic activity, particularly in premenopausal women and children. Pharmacokinetic studies have shown that genistein is absorbed following oral administration with bioavailability estimated at 20 to 30 percent. The compound undergoes extensive first-pass metabolism through glucuronidation and sulfation, with peak plasma concentrations of 2 to 8 micromolar achieved following oral doses of 50 to 200 milligrams. Genistein exhibits a biphasic elimination pattern with an initial half-life of 2 to 3 hours followed by a longer terminal half-life of approximately 8 hours. Importantly, there is substantial interindividual variation in genistein pharmacokinetics related to differences in gut microbiota composition, as intestinal bacteria play important roles in isoflavone metabolism.

Drug-drug interactions represent an important consideration when phytochemicals are administered in combination with conventional therapies. Many phytochemicals modulate the activity of cytochrome P450 enzymes and drug transporters, potentially altering the pharmacokinetics of co-administered medications. Curcumin has been shown to inhibit multiple cytochrome P450 isoforms including CYP3A4, CYP2C9, and CYP2D6, raising concerns about potential interactions with chemotherapeutic agents and other medications metabolized by these enzymes. Resveratrol can inhibit CYP3A4 and P-glycoprotein, potentially increasing plasma levels of substrate drugs. Epigallocatechin gallate has been shown to modulate multiple drug-metabolizing enzymes and transporters, with effects varying depending on dose and duration of exposure. Quercetin is a well-characterized inhibitor of P-glycoprotein and other ATP-binding cassette transporters, which while potentially beneficial for overcoming drug resistance, also raises concerns about altered drug disposition. Clinical trials evaluating phytochemicals in combination with conventional therapies should include pharmacokinetic assessments to characterize potential interactions and guide appropriate dose adjustments.

Challenges, Regulatory Perspectives, and Future Directions

The development of plant-derived bioactive compounds as standardized therapeutic agents faces numerous challenges spanning scientific, regulatory, and commercial domains. While the preclinical evidence supporting the anticancer potential of phytochemicals is substantial, translation into clinical practice has been hindered by issues related to bioavailability, target identification, clinical trial design, regulatory classification, and intellectual property considerations. Addressing these challenges will require coordinated efforts involving academic researchers, pharmaceutical industry, regulatory agencies, and clinical investigators.

The poor bioavailability and unfavorable pharmacokinetic properties of many phytochemicals represent fundamental barriers to their clinical development. Even when promising molecular mechanisms and potent effects are demonstrated in preclinical models, the inability to achieve adequate tissue concentrations in patients undermines therapeutic potential. The development of advanced pharmaceutical formulations including nanoparticle-based delivery systems, structural analogs with improved properties, and prodrug approaches represents an active area of investigation. Nanomedicine strategies utilizing liposomes, polymeric nanoparticles, solid lipid nanoparticles, and other nanocarriers have shown promise in enhancing bioavailability, prolonging circulation time, and enabling targeted delivery to tumor tissues. However, these advanced formulations introduce additional complexity in terms of manufacturing, characterization, and regulatory requirements.

The pleiotropic nature of phytochemicals, while potentially advantageous for targeting complex diseases, complicates

mechanistic understanding and identification of relevant biomarkers. Unlike targeted therapies directed against specific molecular alterations, phytochemicals typically modulate multiple pathways simultaneously, making it challenging to establish clear cause-effect relationships between molecular changes and therapeutic outcomes. This mechanistic complexity also complicates patient selection strategies, as it remains unclear which tumor characteristics or molecular profiles might predict response to these agents. The application of systems biology approaches integrating multi-omics data may help elucidate the dominant molecular effects of phytochemicals in different cellular contexts and identify predictive biomarkers.

Clinical trial design for phytochemicals presents unique challenges related to study population selection, appropriate endpoints, and interpretation of results. Many early trials employed heterogeneous patient populations without molecular stratification, potentially diluting treatment effects in responsive subgroups. The long latency period of cancer development and the potential for phytochemicals to act primarily in cancer prevention or early intervention settings necessitate trials of extended duration with large sample sizes to detect meaningful effects on cancer incidence or survival. The selection of appropriate doses for clinical evaluation is complicated by the disconnect between concentrations showing efficacy in preclinical models and those achievable in patients. Adaptive trial designs that allow dose optimization and incorporation of pharmacodynamic endpoints may help address these challenges.

The regulatory classification of plant-derived compounds exists in a gray area between dietary supplements, which are subject to minimal regulatory oversight, and pharmaceutical drugs, which require extensive safety and efficacy data for approval. In many jurisdictions, phytochemical products are marketed as dietary supplements without the need for premarket approval, though manufacturers are restricted in the health claims they can make. This regulatory framework has led to a proliferation of products with variable quality, potency, and composition, contributing to inconsistent results across studies. The development of phytochemicals as approved therapeutic agents would require conducting rigorous phase I, II, and III clinical trials according to good clinical practice guidelines and obtaining marketing authorization from regulatory agencies. However, the natural origin of these compounds often precludes patent protection, reducing commercial incentives for pharmaceutical companies to invest in expensive clinical development programs.

Standardization and quality control represent critical challenges for phytochemical research and clinical application. Plant-derived compounds can vary substantially in composition depending on factors including plant source, growing conditions, harvesting time, extraction methods, and storage conditions. The presence of related compounds, impurities, and botanical matrix components can influence biological activity and complicates comparisons across studies. Development of pharmaceutical-grade preparations with defined composition, purity, and potency is essential for rigorous clinical evaluation. Analytical methods including high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy enable comprehensive characterization of phytochemical preparations. The integration of phytochemicals into precision oncology paradigms represents a promising future direction. As our understanding of cancer molecular subtypes continues to evolve and as technologies for comprehensive molecular profiling become more accessible, it may become possible to identify specific patient populations most likely to benefit from particular phytochemicals. For example, tumors with specific pathway alterations, biomarker profiles, or metabolic characteristics might be particularly sensitive to certain plant-derived compounds. The development of companion diagnostics that can predict response to phytochemicals would facilitate their rational clinical application.

The potential for combining phytochemicals with emerging therapeutic modalities including immunotherapy and targeted therapy warrants investigation. Preclinical evidence suggests that some phytochemicals can modulate immune cell function, alter the tumor microenvironment, and potentially enhance responses to immune checkpoint inhibitors. Similarly, the capacity of phytochemicals to overcome resistance to targeted therapies through modulation of compensatory signaling pathways suggests potential for rational combination strategies. Clinical trials evaluating these novel combinations are beginning to emerge.

The application of artificial intelligence and machine learning approaches to phytochemical research may accelerate discovery and development. Computational methods can predict molecular interactions, identify potential synergies between compounds, optimize formulations, and analyze complex multi-omics datasets to identify mechanisms of action and predictive biomarkers. Virtual screening of natural product databases may enable identification of novel compounds with desired properties. Integration of electronic health records, biobank resources, and real-world evidence may facilitate efficient evaluation of phytochemicals in large patient populations.

Conclusion

Plant-derived bioactive compounds represent a promising class of therapeutic agents for cancer treatment and prevention, distinguished by their capacity to modulate multiple signaling pathways simultaneously and their generally favorable safety profiles. The extensive preclinical evidence demonstrating that phytochemicals including curcumin, resveratrol, epigallocatechin gallate, quercetin, and genistein can effectively target key cancer signaling pathways provides a strong scientific foundation for their clinical development. These compounds exert their anticancer effects through diverse mechanisms including inhibition of the phosphoinositide 3-kinase/protein kinase B pathway, modulation of mitogen-activated protein kinase signaling, suppression of Wnt/β-catenin and nuclear factor-kappa B pathways, induction of apoptosis, promotion of cell cycle arrest, inhibition of angiogenesis, and suppression of metastatic potential. The multi-targeting properties of phytochemicals may offer advantages over conventional single-target therapies, particularly in addressing tumor heterogeneity and preventing resistance development.

However, significant challenges must be overcome to realize the full therapeutic potential of plant-derived compounds in clinical oncology. The poor bioavailability and unfavorable pharmacokinetic properties of many phytochemicals limit achievement of therapeutically relevant tissue concentrations, necessitating development of improved formulations and delivery strategies. The mechanistic complexity of phytochemicals complicates identification of

optimal patient populations and predictive biomarkers. Clinical trials conducted to date have yielded mixed results, with some studies demonstrating promising signals while others have failed to show significant clinical benefits. These inconsistent outcomes reflect multiple factors including heterogeneous patient populations, suboptimal dosing, variable product quality, and challenges in trial design.

The future development of plant-derived anticancer agents should focus on several key priorities. First, continued efforts to enhance bioavailability through advanced pharmaceutical formulations including nanoparticle-based delivery systems are essential. Second, comprehensive pharmacokinetic and pharmacodynamic studies should be integrated into clinical trials to establish optimal dosing regimens and to characterize relationships between drug exposure and clinical effects. Third, molecular profiling studies should be conducted to identify tumor characteristics and patient factors that predict response to specific phytochemicals, enabling precision medicine approaches. Fourth, rigorous evaluation of combination strategies integrating phytochemicals with conventional therapies and emerging modalities should be pursued, as these approaches may offer the greatest near-term clinical utility. Fifth, standardization of phytochemical preparations and establishment of quality control standards are imperative to ensure reproducibility across studies and to enable evidence-based clinical application.

The successful translation of several plant-derived compounds including paclitaxel, vincristine, and vinblastine into standard oncology practice demonstrates that natural products can indeed become valuable cancer therapeutics when their mechanisms are fully elucidated, their pharmaceutical properties are optimized, and rigorous clinical evaluation is conducted. While the phytochemicals discussed in this review have not yet achieved this level of clinical validation, the substantial preclinical evidence supporting their anticancer potential, coupled with ongoing efforts to address current limitations, suggests that plant-derived compounds will continue to play important roles in cancer therapy and prevention. As our understanding of cancer biology becomes increasingly sophisticated and as technologies for drug delivery and patient selection continue to advance, plant-derived bioactive compounds may ultimately fulfill their promise as components of precision oncology approaches that maximize therapeutic benefit while minimizing toxicity.

Figures



Fig 1: Major cancer signaling pathways targeted by plant-derived bioactive compounds, including PI3K/Akt, MAPK, Wnt/β-catenin, and NF-κB.



Fig 2: Mechanistic overview of apoptosis, cell cycle arrest, and angiogenesis inhibition induced by selected phytochemicals.



Fig 3: Translational pipeline from preclinical evaluation to clinical application of plant-derived anticancer agents.



Fig 4: Synergistic effects of plant-derived compounds in combination with conventional chemotherapeutics.

References

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, *et al*. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
3. Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12(1):3-20.
4. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.
5. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103-119.
6. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192-1205.
7. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670-3695.
8. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, *et al*. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582-1614.
9. Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci. 2013;34(9):508-517.
10. Wink M. Modes of action of herbal medicines and plant secondary metabolites. Medicines (Basel). 2015;2(3):251-286.
11. Newman DJ, Cragg GM. Natural products as sources of new drugs over nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803.

12. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009;109(7):3012-3043.
13. Gali-Muhtasib H, Hmadi R, Kareh M, Tohme R, Darwiche N. Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis. Apoptosis. 2015;20(12):1531-1562.
14. Greenwell M, Rahman PK. Medicinal plants: their use in anticancer treatment. Int J Pharm Sci Res. 2015;6(10):4103-4112.
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
16. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
17. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719-724.
18. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117-1134.
19. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605-635.
20. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655-1657.
21. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261-1274.
22. Hers I, Vincent EE, Tavare JM. Akt signaling in health and disease. Cell Signal. 2011;23(10):1515-1527.
23. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283-296.
24. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127-150.
25. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50-83.
26. Morrison DK. MAP kinase pathways. Cold Spring Harb Perspect Biol. 2012;4(2):a011254.
27. Keshet Y, Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol. 2010;661:3-38.
28. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279-3290.
29. Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80(14):2969-2974.
30. Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985-999.
31. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9-26.
32. Stamos JL, Weis WI. The β-catenin destruction complex. Cold Spring Harb Perspect Biol. 2013;5(10):a007898.
33. Cadigan KM, Waterman ML. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol. 2012;4(11):a007906.
34. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4(5):a008052.
35. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-759.
36. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132(3):344-362.
37. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023.
38. Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309-324.
39. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651.
40. Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res. 2014;2(9):823-830.
41. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075-1083.
42. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS. Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008;22(11):1490-1500.
43. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320-328.
44. Kaushik I, Ramachandran S, Prasad S, Srivastava SK. Drug rechanneling: a novel paradigm for cancer treatment. Semin Cancer Biol. 2021;68:279-290.
45. Weng JK, Philippe RN, Noel JP. The rise of chemodiversity in plants. Science. 2012;336(6089):1667-1670.
46. Howes MJR, Quave CL, Collemare J, Tatsis EC, Twilley D, Lulekal E, *et al*. Molecules from nature: reconciling biodiversity conservation and global healthcare imperatives for sustainable use of medicinal plants and fungi. Plants People Planet. 2020;2(5):463-481.
47. Sharifi-Rad J, Quispe C, Castillo CMS, Caroca R, Lafranconi A, Garg N, *et al*. Plant natural products with anti-cancer potential: a comprehensive review. Anticancer Agents Med Chem. 2021;21(14):1880-1891.
48. Salehi B, Venditti A, Sharifi-Rad M, Kręgiel D, Sharifi-Rad J, Durazzo A, *et al*. The therapeutic potential of apigenin. Int J Mol Sci. 2019;20(6):1305.
49. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195-218.
50. Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, *et al*. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325-1348.
51. Giordano A, Tommonaro G. Curcumin and cancer. Nutrients. 2019;11(10):2376.
52. Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, *et al*. The multifaceted role of curcumin in cancer prevention and treatment. Molecules. 2015;20(2):2728-2769.